Kim Hofman

Kim Hofman has four years of experience in the biotechnology industry. In 2020, they began working as a Research Associate at Lava Therapeutics B.V., a biotechnology company that creates and develops next generation γδ T cell engaging bispecific antibodies for the treatment of cancer. Prior to this, they completed research internships at Sanquin in 2018 and AIMM Therapeutics in 2018, as well as a research internship at Universiteit van Amsterdam in 2017.

Kim Hofman completed a Bachelor of Science in Biomedical Sciences from the University of Amsterdam between 2014 and 2017. Kim then went on to complete a Master of Science in Biomedical Sciences (Oncology track) from the University of Amsterdam between 2017 and 2019.